US · AVR
Anteris Technologies Global Corp.
- Sector
- Healthcare · Medical - Devices
- Headquarters
- Toowong, QLD 4066
- Website
- anteristech.com
Price · as of 2025-12-31
$6.36
Market cap 239.49M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $21.44 | +237.11% |
| Intrinsic Value(DCF) | $2.76 | -56.6% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | $79.13 | +1,144.18% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | |||||
| 2021 | $0.00 | $0.00 | |||
| 2022 | $0.00 | $29.85 | |||
| 2023 | $0.00 | $7.47 | |||
| 2024 | $7.56 | $13.77 | $0.00 | $0.00 | $0.00 |
| 2025 | $6.62 | $21.44 | $0.23 | $0.00 | $79.13 |
AI valuation
Our deep-learning model estimates Anteris Technologies Global Corp.'s (AVR) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $21.44
- Current price
- $6.36
- AI upside
- +237.11%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$2.76
-56.6% upside
Graham-Dodd
—
— upside
Graham Formula
$79.13
+1,144.18% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| AVR | Anteris Technologies Glob… | $6.36 | 239.49M | +237% | -57% | — | +1,144% | -1.66 | -1678.27 | 81.59 | -1.58 | -27.15 | -987.84 | 70.26% | 24.41% | -4925.51% | -300.71% | -5.60% | -181.73% | -24.54 | 6.40 | 0.73 | 0.59 | 0.11 | 610.00% | -2923.00% | 2251.00% | -49.85% | -3.64 | 932.39% | 0.00% | 0.00% | 0.00% | 312.17 | -1.87 | 76.21 | -18.68 |
| ANIK | Anika Therapeutics, Inc. | $14.36 | 207.09M | +157% | -53% | -61% | — | -18.87 | 1.43 | 1.82 | -93.81 | — | 1.54 | 56.56% | -9.80% | -9.64% | -7.32% | -9.43% | -5.54% | 0.17 | -6.34 | 4.72 | 3.71 | 18.15 | -8016.00% | -591.00% | -28713.00% | 2.12% | 0.51 | 3.72% | 0.00% | 0.00% | 6.37% | -15.57 | 39.44 | 1.53 | 3.99 |
| ARAY | Accuray Incorporated | $0.58 | 68.6M | +5,263% | +4% | -74% | — | -97.54 | 1.91 | 0.34 | 13.55 | — | 6.65 | 32.05% | 1.71% | -0.35% | -2.52% | 1.62% | -0.34% | 2.17 | 0.61 | 1.65 | 0.81 | 5.88 | -9031.00% | 268.00% | -6348.00% | -3.65% | 0.01 | -2.92% | 0.00% | 0.00% | 14.96% | 34.97 | -48.41 | 0.60 | 0.04 |
| ATLN | Atlantic International Co… | $3.15 | 223.78M | +816% | -55% | — | — | -0.97 | -10.93 | 0.30 | -1.89 | -0.19 | -3.02 | 10.66% | -4.93% | -30.61% | 527.46% | -25.40% | -108.64% | -6.88 | -1.82 | 0.91 | 0.76 | -0.73 | 51333.00% | 1027.00% | -3383.00% | -4.61% | -0.06 | -7.05% | 0.00% | 0.00% | 45.10% | -9.77 | -35.22 | 0.48 | 1.97 |
| LNSR | LENSAR, Inc. | $11.97 | 142.98M | +705% | -42% | — | — | -5.45 | 9.18 | 3.20 | -50.35 | -5.03 | 13.66 | 48.33% | -19.94% | -58.71% | -95.42% | -88.05% | -46.22% | 0.14 | — | 2.80 | 1.93 | 4.54 | 10840.00% | 2687.00% | -7543.00% | -1.42% | -0.15 | -20.07% | 0.00% | 0.00% | 0.00% | -14.19 | -62.24 | 2.83 | -0.11 |
| LUCD | Lucid Diagnostics Inc. | $1.44 | 146.54M | +85,309% | -60% | — | — | -1.54 | 13.02 | 16.16 | -1.56 | — | 15.08 | -90.20% | -1059.64% | -1047.61% | -2956.43% | 5531.77% | -157.04% | 3.94 | -1771.23 | 1.07 | 0.97 | 0.02 | -1667.00% | 7900.00% | 3556.00% | -63.78% | -1.88 | 5379.70% | 0.00% | 0.00% | 0.00% | -1.50 | -1.54 | 15.90 | -12.37 |
| MXCT | MaxCyte, Inc. | $0.81 | 86.54M | +3,073% | +164% | -99% | — | -8.96 | 1.78 | 9.53 | -4.99 | -165.84 | 1.78 | 81.62% | -132.54% | -106.29% | -18.73% | -67.18% | -16.17% | 0.09 | — | 10.88 | 10.09 | 0.21 | 541.00% | -644.00% | 1526.00% | -7.95% | -1.75 | -38.39% | 0.00% | 0.00% | 0.00% | -4.52 | -7.91 | 6.00 | 5.62 |
| NKTX | Nkarta, Inc. | $2.70 | 191.78M | — | — | — | — | -1.15 | 0.31 | — | 0.52 | — | 0.31 | 0.00% | — | — | -31.94% | -76.69% | -24.72% | 0.20 | — | 14.45 | 14.14 | -0.44 | -3333.00% | — | -893.00% | -83.37% | -5.27 | -62.28% | 0.00% | 0.00% | 3.92% | 0.49 | 0.60 | — | -0.95 |
| OWLT | Owlet, Inc. | $11.55 | 184.81M | +401% | +393% | — | — | -5.81 | -3.44 | 0.93 | -6.80 | — | -3.29 | 50.36% | -25.90% | -16.06% | 49.33% | 68.11% | -26.78% | -0.56 | -12.40 | 1.27 | 0.89 | 0.88 | -8168.00% | 4452.00% | -4925.00% | -16.44% | -0.31 | 40.32% | 0.00% | 0.00% | 11.27% | -3.19 | -5.38 | 0.83 | -6.50 |
| SAVA | Cassava Sciences, Inc. | $2.28 | 110.14M | — | — | — | — | -5.35 | 0.89 | — | -0.01 | — | 0.89 | 0.00% | — | — | -17.19% | -845.41% | -15.75% | 0.00 | — | 11.62 | 11.02 | 0.91 | -7759.00% | — | 4196.00% | -89.90% | -9.95 | -699.49% | 0.00% | 0.00% | 5.71% | -0.01 | -0.01 | — | 0.99 |
About Anteris Technologies Global Corp.
Anteris Technologies Global Corp., a structural heart company, discovers, develops, and commercializes medical devices to enhance the quality of life for patients with aortic stenosis. Its lead product candidate is the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also devlops ADAPT anti-calcification tissue, an anti-calcification preparation that transforms xenograft tissue into durable bioscaffolds that are used to mimic human tissue for surgical repair in multiple settings, including aortic valve replacement; and ComASUR delivery system, a physician-developed balloon expandable delivery system that contains a reinforced steerable catheter for a precise deflection through the heart anatomy in a controlled manner to avoid damage to the aorta. Anteris Technologies Global Corp. was incorporated in 1999 and is based in Toowong, Australia.
- CEO
- Wayne Geoffrey Paterson
- Employees
- 136
- Beta
- 1.32
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($2.76 ÷ $6.36) − 1 = -56.6% (DCF, example).